Su1334 Eus-Fna in Surgically Proven Pancreatic Neuroendocrine Tumors: A Large Single Center Experience

Pancreatic neuroendocrine tumors (pNET) are rare neoplasms, occurring in less than 1 out of 100,000 people per year and representing 1-2% of all pancreatic tumors. While resection is the only curative treatment for localized disease, it remains a debated management option as many low-grade and intermediate-grade tumors have indolent clinical courses. We reviewed our tertiary center’s large experience of nonfunctioning pNETs and assessed the diagnostic yield of EUS-FNA with respect to Ki-67 index, tumor size, mitotic rate, lymph node involvement (LN+), lymphovascular invasion (LVI+) or other invasive features (peripancreatic fat, neural, perineural, splenic or duodenal invasion) at the time of surgical resection.